Narnatumab

Drug Profile

Narnatumab

Alternative Names: IMC-RON-8; RON-8

Latest Information Update: 07 Oct 2013

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator ImClone Systems
  • Developer Eli Lilly; ImClone Systems
  • Class Monoclonal antibodies
  • Mechanism of Action RON protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Solid tumours

Most Recent Events

  • 18 Sep 2013 Discontinued - Phase-I for Solid tumours (late-stage disease) in USA (IV)
  • 16 Nov 2011 Pharmacodynamics data from a preclinical trial in Solid tumours presented at the 23rd AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (AACR-NCI-EORTC-2011)
  • 01 May 2010 Phase-I clinical trials in Solid tumours (late-stage disease) in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top